- Home
- CRBG vs NBIX Comparison
CRBG vs NBIX Comparison
Compare CRBG & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBG | NBIX |
|---|---|---|
| Founded | 1957 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0B | 13.9B |
| IPO Year | 2022 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CRBG | NBIX |
|---|---|---|
| Price | $22.98 | $126.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 22 |
| Target Price | $36.38 | ★ $175.27 |
| AVG Volume (30 Days) | ★ 3.5M | 858.3K |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 4.67 |
| Revenue | ★ $18,481,000,000.00 | $161,626,000.00 |
| Revenue This Year | $16.58 | $22.85 |
| Revenue Next Year | $5.58 | $9.99 |
| P/E Ratio | ★ N/A | $27.76 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $22.32 | $84.23 |
| 52 Week High | $36.57 | $160.18 |
Technical Indicators
Market Signals| Indicator | CRBG | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 31.47 | 42.17 |
| Support Level | $22.32 | $122.82 |
| Resistance Level | $32.74 | $128.99 |
| Average True Range (ATR) | 0.98 | 2.99 |
| MACD | -0.04 | 0.14 |
| Stochastic Oscillator | 17.35 | 15.83 |
Price Performance
Historical ComparisonAbout CRBG Corebridge Financial Inc.
Corebridge Financial Inc provides retirement solutions and insurance products in the United States. It offers a broad set of products and services through five segments Individual Retirement, Group Retirement, Life Insurance, Institutional Markets businesses, Corporate and Other. The majority of its revenue derives from the Individual Retirement segment.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.